Jaguar Health Issues Shares to Convert Preferred Stock, Adjourns Annual Meeting Amidst Dilution Concerns
JAGX is trading near its 52-week low of $2.53 (15% above the low) on elevated volume (2.0× avg).
Summary
Jaguar Health issued common stock to convert preferred shares, causing significant dilution, and adjourned its annual meeting to address shareholder concerns over pending proposals.
Key Events · Financing and Capital Events · JAGX
-
Significant Dilution from Preferred Stock Conversion
Jaguar Health issued 54,222 common shares to Streeterville Capital, LLC in exchange for 7.96 shares of Series Q Perpetual Preferred Stock, which were then cancelled. This transaction, valued at approximately $157,244 based on the current stock price, represents a substantial dilution for existing common shareholders.
-
Annual Meeting Adjourned for Additional Information
The company adjourned its 2026 Annual Meeting of Stockholders until June 2, 2026. The adjournment is to provide additional information to stockholders regarding certain proposals in the definitive proxy statement, which previously included highly dilutive financing agreements. This indicates potential difficulties in gaining shareholder approval for critical capital structure changes.
Analysis · JAGX · Life Sciences
Jaguar Health issued common stock to Streeterville Capital, LLC, converting preferred shares and resulting in significant dilution for existing shareholders. This transaction, valued at approximately $157,244, represents a substantial portion of the company's current market capitalization. Concurrently, the company adjourned its annual meeting, citing a need to provide additional information regarding proposals in its proxy statement. This suggests potential challenges in securing shareholder approval for critical financing or capital structure changes, which have previously included highly dilutive agreements.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $2.53 to $171.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.